Clinical Trials in Shrewsbury, United Kingdom
6 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Not Applicable
Shortened High-dose Palliative Radiotherapy for Lung Cancer
Stage IV Lung Cancer
University Hospitals Coventry and Warwickshire NHS Trust37 enrolled4 locationsNCT06483308
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
Breast CancerSentinel Lymph Node Biopsy (SLNB)Axillary Lymph Nodes Dissection+1 more
University Hospitals of Derby and Burton NHS Foundation Trust200 enrolled10 locationsNCT07085442
Recruiting
Not Applicable
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy
Breast CancerSentinel Lymph NodeNeoplasm, Breast
University Hospitals of Derby and Burton NHS Foundation Trust1,900 enrolled98 locationsNCT04109079
Recruiting
Not Applicable
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Kidney Failure, ChronicHyperphosphatemia
The University of Queensland3,600 enrolled115 locationsNCT03573089
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Phase 4
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
End-stage Kidney Disease
University of Sydney50,000 enrolled264 locationsNCT02823821
Recruiting
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
Colorectal, Cancer
Royal Marsden NHS Foundation Trust1,000 enrolled71 locationsNCT04050345